Georgia Governor Brian Kemp has signed into law “The Putting Georgia Patients First Act,” significantly expanding medical cannabis access for qualifying patients across the state. The legislation introduces new qualifying conditions and permits additional methods of administration, aiming to provide options for individuals with specific medical needs. This development was reported by WTOC on May 27, 2026.
Expanded Qualifying Conditions and Patient Registry Updates
The newly enacted law broadens the list of medical conditions that qualify patients for medical cannabis. Specific conditions such as lupus and Crohn’s disease have been added to the state’s medical cannabis patient registry, reflecting an updated understanding of conditions that may be considered for cannabinoid therapies. This expansion is intended to address a wider range of chronic and debilitating illnesses, offering options beyond traditional pharmaceuticals for a larger patient population.
Gary Long, CEO of Botanical Sciences, commented on the expanded access, noting its potential to assist patients who previously had limited treatment options. “I think we all know somebody who suffers and they probably suffer unnecessarily from a lot of these conditions,” Long stated, highlighting the legislative intent to provide alternatives to conventional pharmaceutical regimens. Furthermore, the legislation amends the previous “low THC” wording in the patient registry. This change moves towards a more comprehensive “medical cannabis patient registry,” indicating a broader regulatory scope for the types of medical cannabis products available to registered patients.
THC Limits and Permitted Administration Methods
“The Putting Georgia Patients First Act” introduces specific changes regarding THC limits and approved delivery methods. Under the new provisions, the permissible THC limit for patient possession has been increased to 12,000 milligrams. Gary Long clarified this aspect, stating, “There isn’t a cap on the potency side of things, but there is a limit as to how much somebody could possess at any one given point in time.” This distinction is crucial for both patients and licensed cultivators or dispensaries, providing clear parameters for product formulation and patient acquisition.
A significant change introduced by the Act is the allowance for inhalation methods of medical cannabis for Georgians aged 21 and older. This provision is designed to offer a quicker onset of effect, particularly for acute symptoms where a rapid therapeutic effect may be desired. Long explained that “inhaling it in the form that we’re going to be able to sell will give folks pretty much instantaneous relief,” addressing a common patient need for immediate symptom management. This represents a notable shift in the state’s approach to medical cannabis delivery, moving beyond solely oral or topical applications.
Patient Outcomes and Program Integrity
The expansion of medical cannabis access has garnered feedback from patients and their families. Sam Hodges, an Effingham mother, shared her experience regarding the use of THC oil for her baby, who previously experienced frequent seizures. “To us its been life saving. Ever since he started the medical cannabis, he went from 20 to 40 seizures a day to none,” Hodges reported, underscoring the potential impact for severe and refractory conditions. This anecdotal evidence highlights the impact of expanded access on patient quality of life.
Tarun Goyal of Miracle Leaf emphasized the importance of maintaining the medical integrity of the program. Goyal stated, “We must understand, this is a medical piece, so please do not go ahead and obtain because you want to just smoke. It’s really helps because the THC bud that’s provided to you is for medical graded not just to get high.” This statement reinforces the program’s focus on legitimate medical use and distinguishes it from recreational consumption. Such clarifications are critical for ensuring compliance and public understanding of the regulatory framework governing medical cannabis in Georgia.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
